| Literature DB >> 35518898 |
Hichem Sebai1, Kaïs Rtibi1, Slimen Selmi1, Mourad Jridi2, Rafik Balti1, Lamjed Marzouki1.
Abstract
Cinnamon bark and evergreen oak acorns, natural sources of functional ingredients, are effective for those suffering from diarrhea, constipation and irritable bowel syndrome. This study aimed to evaluate the dissimilar phytochemical composition and the opposite potential actions of Cinnamomum cassia bark (ACCE) and Quercus ilex aqueous extracts (GIAE) on gastrointestinal (GI)-physiological activities and disruptions. An HPLC-PDA/ESI-MS assay was used to identify the distinctive qualitative and quantitative profiles of phenolic compounds. The GI-physiological action of both extracts on gastric emptying (GE) and gastrointestinal transit time (GIT) were evaluated using the phenol-red colorimetric method and a test meal containing charcoal/gum arabic in water. Loperamide (LOP)-induced colonic constipation and delayed emptying of the stomach were used to explore the reverse effects of ACCE/GIAE on GI disorders. HPLC-PDA/ESI-MS showed that the main phenolic compounds detected in ACCE are trans-cinnamic acid, quinic acid, protocatechuic acid and rosmarinic acid, while gallic acid, quinic acid and protocatechuic acid are the major chemical constituents found in GIAE. GIAE at two doses (150 and 300 mg kg-1) exerted a reduction of GE (66.40% and 60.87%, respectively) compared to a control group (70.25%). However, ACCE at the same concentrations induced contradictory actions on GE/GIT in comparison to GIAE and antagonistic synthetic pharmacological drugs in rats. The protective effect of CCAE against constipation induced by LOP in rats was accompanied by a strong antioxidant property related to moderation of intracellular-mediator disorders. An absence of toxic actions was revealed in the case of the hematological profile and biochemical parameters. Hence, in-depth investigations of these nutrients of both extracts may help future researchers to derive the underlying mechanisms and potential molecular targets for the development of physiologically functional foods and future therapies. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35518898 PMCID: PMC9066441 DOI: 10.1039/c9ra02429h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
High-resolution liquid chromatography/electrospray ionization (LC-HRESIMS) identification of both extracts (ACCE and GIAE)
| Name | Molecular formula | PubChem CID | [M]−H | ACCE | GIAE | ||
|---|---|---|---|---|---|---|---|
| Retention time | Concentration (ppm) | Retention time | Concentration (ppm) | ||||
| Quinic acid | C7H12O6 | 6508 | 191.00 | 2.011 | 191.462 | 2.037 | 307.485 |
| Gallic acid | C7H6O5 | 370 | 169.00 | 3.986 | 4.198 | 3.989 | 358.708 |
| Protocatechuic acid | C7H6O4 | 72 | 153.00 | 6.925 | 155.249 | 6.955 | 8.606 |
| Catechin(+) | C15H14O6 | 73160 | 289.00 | — | ND | 11.260 | 0.469 |
| Chlorogenic acid | C16H18O9 | 1794427 | 353.00 | 11.602 | 2.762 | 11.624 | 0.423 |
| 4- | C16H18O9 | 5281780 | 353.00 | 11.602 | 2.821 | 11.624 | 0.442 |
| Caffeic acid | C9H8O4 | 689043 | 179.00 | 14.581 | 1.587 | — | ND |
| Syringic acid | C9H10O5 | 10742 | 197.00 | 16.206 | 6.281 | 16.216 | 2.727 |
| Epicatechin | C15H14O6 | 72276 | 289.00 | 16.993 | 10.063 | — | ND |
|
| C9H8O3 | 637542 | 163.00 | 21.017 | 7.184 | 21.108 | 7.120 |
|
| C10H10O4 | 445858 | 193.00 | 23.269 | 2.845 | 23.317 | 0.954 |
| Hyperoside (quercetin-3- | C21H20O12 | 5281643 | 463.00 | 24.792 | 0.438 | — | ND |
|
| C9H8O3 | 637540 | 163.00 | 26.367 | 1.792 | — | ND |
| Luteolin-7- | C21H20O11 | 5280637 | 447.00 | 24.853 | 1.913 | — | ND |
| Quercetrin (quercetin-3- | C21H20O11 | 15939939 | 447.00 | 26.958 | 0.734 | — | ND |
| Rosmarinic acid | C18H16O8 | 5315615 | 359.00 | 26.473 | 86.058 | — | ND |
| Naringin | C27H32O14 | 442428 | 579.00 | — | ND | 26.218 | 2.256 |
| Apigenin-7- | C21H20O10 | 45933926 | 431.00 | 27.147 | 0.567 | — | ND |
| 4,5-Di- | C25H24O12 | 6474309 | 515.00 | 26.961 | 0.269 | — | ND |
|
| C9H8O2 | 444539 | 147.00 | 32.158 | 1105.222 | 32.133 | 0.919 |
| Quercetin | C15H10O7 | 5280343 | 301.00 | 32.140 | 0.292 | 32.124 | 0.063 |
| Kaempferol | C15H10O6 | 5280863 | 285.00 | 32.197 | 0.156 | 32.228 | 0.023 |
| Naringenin | C15H12O5 | 439246 | 271.00 | 34.130 | 0.196 | — | ND |
| Silymarin | C25H22O10 | 31553 | 481.00 | 34.000 | 0.516 | — | ND |
| Apigenin | C15H10O5 | 5280443 | 269.00 | 35.016 | 0.215 | 34.633 | 0.019 |
| Luteolin | C15H10O6 | 5280445 | 285.00 | 34.718 | 0.386 | 35.222 | 0.027 |
| Cirsiliol | C17H14O7 | 160237 | 329.00 | 35.809 | 6.451 | 35.820 | 1.559 |
| Cirsilineol | C18H16O7 | 162464 | 343.00 | 39.093 | 0.040 | 39.073 | 0.033 |
The compounds are suggested according to the dictionary of natural products and the characteristic fragmentation pattern.
The formulae were deduced from the quasi molecular ion peak [M + H]+.
Fig. 1Chromatographic profile and characterization of phenolic compounds of ACCE.
Fig. 2Chromatographic profile and characterization of phenolic compounds of GIAE.
Effects of ACCE and GIAE on hematological parameters in sub-acute toxicity studya
| Hemoglobin (g dL−1) | RBC count (×106 μL−1) | WBC count (×103 μL−1) | Platelet count (×103 μL−1) | ||
|---|---|---|---|---|---|
| NaCl | (10 mL kg−1) | 17.46 ± 0.33 | 4.78 ± 0.12 | 10.62 ± 1.13 | 799.34 ± 23.65 |
| ACCE | (300 mg kg−1) | 14.55 ± 0.34 | 4.57 ± 0.14 | 12.18 ± 0.44 | 812.76 ± 32.90 |
| (700 mg kg−1) | 13.82 ± 0.27 | 5.32 ± 0.15 | 9.62 ± 0.14 | 819.54 ± 25.88 | |
| GIAE | (300 mg kg−1) | 14.33 ± 0.55 | 5.11 ± 0.13 | 11.54 ± 1.14 | 811.22 ± 27.66 |
| (700 mg kg−1) | 15.72 ± 0.66 | 5.32 ± 0.10 | 13.34 ± 0.83 | 784.78 ± 33.55 | |
ACCE/GIAE actions reflected by indicated hematological parameters and assessed in healthy and treated rats. Data are expressed as mean ± standard error (n = 6).
Effects of ACCE and GIAE on biochemical parameters in sub-acute toxicity studya
| Triglycerides (mg dL−1) | Total cholesterol (mg dL−1) | Creatinine (mg dL−1) | ALT (U L−1) | AST (U L−1) | ||
|---|---|---|---|---|---|---|
| NaCl | (10 mL kg−1) | 72.35 ± 5.17 | 85.65 ± 5.71 | 1.52 ± 0.16 | 45.04 ± 1.19 | 55.27 ± 2.39 |
| ACCE | (300 mg kg−1) | 64.12 ± 4.21 | 87.94 ± 6.12 | 1.77 ± 0.21 | 49.15 ± 3.77 | 58.51 ± 2.44 |
| (700 mg kg−1) | 67.11 ± 5.10 | 91.52 ± 5.16 | 1.58 ± 0.14 | 47.66 ± 2.37 | 60.21 ± 1.28 | |
| GIAE | (300 mg kg−1) | 64.55 ± 3.24 | 87.47 ± 3.18 | 1.48 ± 0.10 | 44.22 ± 3.56 | 54.17 ± 2.11 |
| (700 mg kg−1) | 73.81 ± 4.00 | 95.44 ± 4.23 | 1.55 ± 0.23 | 50.33 ± 3.94 | 57.91 ± 3.23 | |
ACCE/GIAE actions reflected by indicated biochemical parameters and assessed in healthy and treated rats. Data are expressed as mean ± standard error (n = 6).
Fig. 3Effect of ACCE/GIAE or LOP on gastric emptying. Animals were treated 1 h prior to a test meal (50 mg of phenol red in 100 mL of aqueous methyl cellulose) with diverse doses of ACCE/GIAE (150 and 300 mg kg−1). Results are expressed as mean ± SEM; n = 6 in each group. Data was analysed by StatView ANOVA. *p < 0.05 compared to control group, #p < 0.05 compared to LOP-group.
Effects of ACCE and reference drugs (clonidine and yohimbine) on gastrointestinal motility in rata
| Rat-groups | Total small intestine length (cm) | GI-motility | ||
|---|---|---|---|---|
| Transit distance of charcoal meal (cm) | GI-charcoal transit (%) | Acceleration/inhibition (%) | ||
| Control (10 mL kg−1) | 83.65 ± 5.66 | 66.25 ± 3.18 | 79.20 ± 3.04 | — |
| Clonidine (1 mg kg−1) | 77.27 ± 4.11 | 30.12 ± 2.77* | 39.00 ± 2.47* | 54.53 |
| Yohimbine (2 mg kg−1) | 86.27 ± 5.02 | 86.03 ± 4.21* | 99.72 ± 2.38* | 30.00 |
| Aqueous extract (ACCE) 150 mg kg−1 | 87.40 ± 3.68 | 75.21 ± 2.56#* | 86.05 ± 4.34#* | 14.00 |
| 300 mg kg−1 | 86.45 ± 3.17 | 82.37 ± 2.162#* | 95.28 ± 3.16#* | 24.33 |
ACCE/drugs modulations reflected by indicated parameters and assessed in healthy and treated rats. Data are expressed as mean ± standard error (n = 7); *p < 0.05 versus control group, #p < 0.05 versus yohimbine/clonidine-groups.
Fecal parameters after LOP caused acute-constipation and protective action of ACCEa
| Rats-group | Fecal parameters on day 5 (collection for 24) | |||
|---|---|---|---|---|
| Fecal pellet ( | Wet weight (g/24 h/rat) | Dry weight (g/24 h/rat) | Water content (%) | |
| CONT (NaCl) | 52.37 ± 2.56 | 4.91 ± 0.55 | 2.02 ± 0.22 | 42.15 ± 3.66 |
| LOP (5 mg kg−1) | 40.23 ± 1.54* | 2.74 ± 0.41* | 1.03 ± 0.14* | 22.43 ± 1.83* |
| ACCE (150 mg kg−1) | 44.53 ± 3.51* | 3.23 ± 0.51* | 1.55 ± 0.32* | 28.24 ± 1.66* |
| (300 mg kg−1) | 48.35 ± 3.60# | 4.32 ± 0.33# | 1.84 ± 0.01# | 37.91 ± 4.15# |
ACCE/drug moderations reflected by indicated fecal-parameters and assessed in healthy and constipated rats. Data are expressed as mean ± standard error (n = 7); *p < 0.05 versus control group, #p < 0.05 versus LOP-group.
Oxidative indicators modulation after LOP caused acute-constipation and corrective action of ACCEa
| MDA (10−3 nmol mg−1 proteins) | –SH (nmol mg−1 proteins) | Carbonylated-proteins (μmol mg−1 proteins) | SOD (10−3 U mg−1 proteins) | CAT (10−3 mol min−1 mg−1 proteins) | ||
|---|---|---|---|---|---|---|
| NaCl | (5 mL kg−1) | 30.45 ± 3.45 | 77.22 ± 6.45 | 19.54 ± 1.523 | 138.44 ± 7.30 | 296.67 ± 11.11 |
| LOP | (5 mg kg−1) | 95.23 ± 5.56* | 37.00 ± 2.77* | 39.29 ± 3.91* | 79.18 ± 5.91* | 188.48 ± 9.00* |
| ACCE | (150 mg kg−1) | 64.34 ± 4.17*# | 47.24 ± 4.21*# | 32.43 ± 2.33*# | 84.11 ± 6.33* | 227.81 ± 8.05*# |
| (300 mg kg−1) | 29.45 ± 4.22# | 68.43 ± 4.50*# | 20.28 ± 0.94# | 111.56 ± 5.12# | 279.98 ± 10.77# | |
ACCE/LOP actions reflected by indicated oxidative stress parameters and assessed in healthy and constipated rats. Data are expressed as mean ± standard error (n = 7); *p < 0.05 versus control group, #p < 0.05 versus LOP-group.
Intracellular-mediators moderation after LOP caused acute-constipation and corrective effect of ACCEa
| H2O2 (μmol mg−1 proteins) | Free iron (nmol mg−1 proteins) | Calcium (10−3 nmol mg−1 proteins) | ||
|---|---|---|---|---|
| NaCl | (5 mL kg−1) | 22.56 ± 2.67 | 24.12 ± 1.32 | 37.00 ± 2.56 |
| LOP | (5 mg kg−1) | 55.43 ± 3.14* | 14.22 ± 0.78* | 19.55 ± 0.95* |
| ACCE | (150 mg kg−1) | 34.90 ± 2.00*# | 17.01 ± 0.44*# | 22.53 ± 1.13*# |
| (300 mg kg−1) | 23.67 ± 0.21# | 25.52 ± 2.77# | 35.28 ± 1.94# | |
ACCE/LOP effects reflected by indicated intracellular mediators and assessed in healthy and constipated rats. Data are expressed as mean ± standard error (n = 7); *p < 0.05 versus control group, #p < 0.05 versus LOP-group.